J. Vredenburgh

发表

Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme

D. Barboriak, H. Friedman, A. Desjardins, 2009, Journal of magnetic resonance imaging : JMRI.

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

John Sampson, Allan H Friedman, A. Friedman, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

H. Friedman, D. Reardon, M. Egorin, 2009, Cancer.

Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

Darell D. Bigner, Allan H. Friedman, Jeremy N. Rich, 2007, Clinical Cancer Research.

CCR 20 th Anniversary Commentary : Bevacizumab in the Treatment of Glioblastoma — The Progress and the

A. Desjardins, J. Vredenburgh, N. Mar, 2015 .

Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme.

J. Kirkpatrick, J. Sampson, J. Vredenburgh, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

R. McLendon, A. Friedman, D. Bigner, 2010, Journal of Neuro-Oncology.

Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy

H. Friedman, D. Reardon, A. Desjardins, 2010, Journal of Neuro-Oncology.

Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.

T. Mikkelsen, W. Yung, M. Prados, 2010, The oncologist.

Experience with irinotecan for the treatment of malignant glioma.

H. Friedman, D. Reardon, A. Desjardins, 2009, Neuro-oncology.

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

R. McLendon, A. Friedman, D. Bigner, 2009, British Journal of Cancer.

Temozolomide in children with progressive low-grade glioma.

A. Friedman, H. Friedman, D. Reardon, 2007, Neuro-oncology.

Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.

D. Berry, O. Colvin, G. Broadwater, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma

A. Friedman, H. Friedman, D. Reardon, 2011, Journal of Neuro-Oncology.

Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.

R. Coleman, R. McLendon, A. Friedman, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Chemotherapy and novel therapeutic approaches in malignant glioma.

A. Friedman, D. Bigner, H. Friedman, 2005, Frontiers in bioscience : a journal and virtual library.

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy

R. McLendon, A. Friedman, H. Friedman, 2009, Journal of Neuro-Oncology.

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.

R. McLendon, A. Friedman, M. Dolan, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER-2 Gene Amplification Correlates with Higher Levels of Angiogenesis and Lower Levels of Hypoxia in Primary Breast Tumors

M. Dewhirst, G. Riggins, A. Lal, 2004, Clinical Cancer Research.

Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.

R. McLendon, J. Kurtzberg, H. Friedman, 2008, Neuro-oncology.

Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.

H. Friedman, D. Reardon, A. Desjardins, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life among patients with Stage II and III breast carcinoma randomized to receive high‐dose chemotherapy with autologous bone marrow support or intermediate‐dose chemotherapy

J. Holland, E. Winer, J. Herndon, 2005, Cancer.

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

A. Friedman, H. Friedman, D. Reardon, 2005, Cancer.

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.

A. Friedman, D. Bigner, J. Provenzale, 2004, Neuro-oncology.

Nonphysician providers in oncology.

J. Vredenburgh, E. O'branski, Susan Blackwell, 2007, Journal of oncology practice.

Treatment exceeds expectations in a patient with non-small cell lung adenocarcinoma with an EGFR exon 20 mutation

J. Vredenburgh, A. McAuliffe, P. Bindal, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.

R. Coleman, R. McLendon, A. Friedman, 2008, Neuro-oncology.

Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients

A. Friedman, H. Friedman, D. Reardon, 2009, Journal of Neuro-Oncology.

J. Kurtzberg, D. Niedzwiecki, G. Broadwater, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.

A. Friedman, D. Bigner, J. Provenzale, 2004, Neuro-oncology.

Phenytoin, Levetiracetam, and Pregabalin in the Acute Management of Refractory Status Epilepticus in Patients with Brain Tumors

B. Kolls, J. Vredenburgh, Christa B. Swisher, 2012, Neurocritical Care.

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.

C. Willett, H. Friedman, D. Reardon, 2012, International journal of radiation oncology, biology, physics.

Thymic hyperplasia after high-dose chemotherapy and autologous stem cell transplantation: incidence and significance in patients with breast cancer.

J. Herndon, E. Patz, H. McAdams, 1999, AJR. American journal of roentgenology.

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

R. McLendon, A. Friedman, K. Aldape, 2011, Neuro-oncology.

Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab

J. Vredenburgh, M. Hadfield, S. Sama, 2019, Cureus.

A phase I trial of gefitinib (ZD1839) plus rapamycin for patients with recurrent malignant glioma

D. Bigner, H. Friedman, D. Reardon, 2005 .

Reply to W. Wick et al

T. Mikkelsen, W. Yung, M. Prados, 2010 .

Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

S. Keir, D. Bigner, H. Friedman, 2013, Journal of neurosurgery.

Phase II Trial of Gliadel plus O 6-Benzylguanine in Adults with Recurrent GlioblastomaMultiforme

R. McLendon, A. Friedman, D. Bigner, 2009 .

Phase II Trial of Gliadel plus O6-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme

R. McLendon, A. Friedman, D. Bigner, 2009, Clinical Cancer Research.

Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma

J. Vredenburgh, P. Bindal, V. Mathew Thomas, 2019, Case Reports in Oncology.

Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results

D. Bigner, H. Friedman, D. Reardon, 2005 .

A phase I dose escalation study of imatinib mesylate plus standard-dosed temozolomide in the treatment of patients with malignant glioma

H. Friedman, D. Reardon, J. Rich, 2005 .

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

R. McLendon, A. Friedman, J. Provenzale, 2005, Cancer.

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma. Authors' reply

H. Friedman, D. Reardon, M. Chamberlain, 2008 .

Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation.

P. N. Rao, Jeffrey S. Miller, J. Vredenburgh, 1999, Blood.

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.

R. Coleman, R. McLendon, A. Friedman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction che

L. Marks, D. Niedzwiecki, G. Broadwater, 2006, Bone Marrow Transplantation.

A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker

J. Vredenburgh, Alla Turshudzhyan, 2020, Current oncology.

Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer.

J. Erasmus, W. Petros, J. Vredenburgh, 1998, American journal of respiratory and critical care medicine.

Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver

D. Berry, W. Petros, J. Vredenburgh, 1998, Bone Marrow Transplantation.

Primary Bone Lymphoma: A Case Series and Review of Literature

J. Vredenburgh, A. Desai, Sudhanshu Mulay, 2020, Case reports in hematology.

Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts

A. Zelenetz, J. Leonard, H. Schoder, 2021, American journal of hematology.

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

Albert Lai, Soonmee Cha, Rajan Jain, 2012, Journal of Neuro-Oncology.

Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support.

W. Petros, N. Chao, J. Vredenburgh, 2000, American journal of respiratory and critical care medicine.

A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow.

R. Bast, L. Layfield, J. Vredenburgh, 1996, Journal of hematotherapy.

Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer

E. Shpall, A. Baron, Y. Nieto, 2004, Clinical Cancer Research.

Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF.

M. Gasparetto, Clay Smith, M. Morse, 2002, Cytokine.

A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy.

H. Lyerly, M. Morse, J. Vredenburgh, 1999, Journal of hematotherapy & stem cell research.

tolerabil-Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme 1 Neuro-oNcology

D. Bigner, H. Friedman, D. Reardon, 2006 .

Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients

D. Barboriak, H. Friedman, D. Reardon, 2008 .

Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells.

D. Rizzieri, N. Chao, J. Vredenburgh, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma

R. McLendon, H. Friedman, D. Reardon, 2013, Journal of Neuro-Oncology.

Posttransplant Lymphoproliferative Disorder Following Nonmyeloablative Allogeneic Stem Cell Transplantation

D. Rizzieri, N. Chao, J. Vredenburgh, 2004, The American journal of surgical pathology.

The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support.

D. Berry, R. Bast, G. Broadwater, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer.

J. Vredenburgh, J. Loewy, K. Dykstra, 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation.

G. Broadwater, D. Rizzieri, N. Chao, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

T. Mikkelsen, W. Yung, M. Prados, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

R. McLendon, A. Friedman, H. Friedman, 2011, Journal of Neuro-Oncology.

A myxoid chondrosarcoma associated with an anti-Hu-positive paraneoplastic encephalomyelitis

C. Singer, J. Vredenburgh, P. Robinson, 2010, Journal of Neuro-Oncology.

Low‐dose weekly paclitaxel for recurrent or refractory aggressive non‐Hodgkin lymphoma

D. Niedzwiecki, C. Decastro, D. Rizzieri, 2004, Cancer.

Alemtuzumab in Relapsed or Refractory Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia

A. Bass, C. Decastro, D. Rizzieri, 2002, Leukemia & lymphoma.

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma 1

A. Friedman, D. Bigner, J. Provenzale, 2004 .

Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report

R. McLendon, M. Morse, J. Vredenburgh, 2010, Case Reports in Oncology.

Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.

G. Rosner, C. Decastro, D. Rizzieri, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.

J. Kurtzberg, V. Hárs, W. Petros, 1995, European journal of haematology.

The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer.

W. Petros, J. Vredenburgh, M. Ross, 1998, American journal of clinical oncology.

Elimination of small cell carcinoma of the lung from human bone marrow by monoclonal antibodies and immunomagnetic beads.

J. Vredenburgh, E. Ball, 1990, Cancer research.

Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG)

H. Friedman, D. Reardon, J. Rich, 2008 .

Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme

A. Friedman, H. Friedman, D. Reardon, 2008 .

Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma

A. Friedman, H. Friedman, D. Reardon, 2008 .

Liver metastases from breast cancer: long-term survival after curative resection.

W. Meyers, M. Morse, P. Clavien, 2000, Surgery.

Myelodysplasia and Acute Leukemia Following High-Dose Chemotherapy

J. Vredenburgh, D. Mcgaughey, 2000 .

Blue toes and a new pair of shoes—Challenges in diagnosis and treatment of acute myelogenous leukemia

J. Vredenburgh, N. Mar, M. Gorgan, 2013, American journal of hematology.

Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer.

W. Petros, J. Vredenburgh, M. Ross, 1996, Bone marrow transplantation.

Impact of consolidation radiotherapy in patients with advanced breast cancer treated with high-dose chemotherapy and autologous bone marrow rescue.

L. Marks, L. Prosnitz, G. Broadwater, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation.

W. Frankel, J. Eastwood, H. Friedman, 2008, Neuro-oncology.

Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting*

J. Vredenburgh, L. Barbato, F. Carter, 2007, Current medical research and opinion.

Dronabinol or Ondansetron Alone and Combined for Delayed Chemotherapy-Induced Nausea and Vomiting (CINV).

Hai-chen Yang, J. Vredenburgh, H. Jhangiani, 2005 .

The Pharmacologic Effects of Recombinant, Human Colony‐Stimulating Factors and Their Modulation by Theophylline

G. Rosner, W. Petros, J. Vredenburgh, 1996, Pharmacotherapy.

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

Allen R. Chen, Zhezhen Jin, P. Richardson, 2002, Blood.

Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.

D. Neuberg, A. Krishnan, P. Richardson, 1998, Blood.

J. Kurtzberg, D. Niedzwiecki, G. Broadwater, 2003 .

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

E. Lipp, H. Friedman, D. Reardon, 2012, Journal of Neuro-Oncology.

Chordoma: A Case Report and Review of Literature

J. Vredenburgh, P. Bindal, A. Noor, 2020, The American journal of case reports.

Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.

A. Friedman, D. Bigner, H. Friedman, 2007, Neuro-oncology.

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

R. McLendon, H. Friedman, D. Reardon, 2012, Journal of Neuro-Oncology.

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma

R. McLendon, H. Friedman, D. Reardon, 2012, Journal of Neuro-Oncology.

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.

F. Aguet, L. Trippa, A. Jakubowiak, 2022, Cancer cell.

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

R. McLendon, P. Wen, A. Norden, 2011, Journal of Neuro-Oncology.

Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.

R. McLendon, A. Friedman, H. Friedman, 2008, Neuro-oncology.

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.

E. Lipp, H. Friedman, D. Reardon, 2015, The oncologist.

Primary Meningeal Rhabdomyosarcoma

R. Riedel, Z. Chang, J. Kirkpatrick, 2011, Sarcoma.

Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas

H. Friedman, D. Reardon, J. Rich, 2008 .

Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.

K. Sullivan, D. Niedzwiecki, C. Decastro, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas

H. Friedman, D. Reardon, J. Rich, 2007 .

Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen.

D. Rizzieri, N. Chao, J. Vredenburgh, 2001, Blood.

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

D. Auclair, A. Jakubowiak, J. Laubach, 2018, Blood.

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

N. Munshi, J. Laubach, P. Richardson, 2018, Blood.

Role of cytokines in autologous bone marrow transplantation.

J. Kurtzberg, W. Petros, J. Vredenburgh, 1993, Hematology/oncology clinics of North America.

Candidemia in women with breast carcinoma treated with high‐dose chemotherapy and autologous bone marrow transplantation

J. Perfect, W. Schell, J. Vredenburgh, 2003, Cancer.

Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer

D. Berry, C. Mckinstry, W. Petros, 1998, Cancer Chemotherapy and Pharmacology.

Cryptococcal meningitis in patients with glioma: a report of two cases

A. Friedman, J. Sampson, J. Vredenburgh, 2008, Journal of Neuro-Oncology.

A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis

E. Paulson, J. Vredenburgh, M. Ross, 1994, Cancer.

Reactivity of anti-CD15 monoclonal antibody PM-81 with breast cancer and elimination of breast cancer cells from human bone marrow by PM-81 and immunomagnetic beads.

J. Vredenburgh, E. Ball, V. Memoli, 1991, Cancer research.

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Raymond Sawaya, Allan H Friedman, Mark R Gilbert, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

Allan H Friedman, James M Provenzale, R. McLendon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy

P. Wen, T. Batchelor, D. Reardon, 2008, Expert opinion on biological therapy.

A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

R. McLendon, A. Friedman, D. Bigner, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.

W. Yung, M. Prados, M. Gilbert, 2010, Neuro-oncology.

The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma

A. Friedman, D. Bigner, H. Friedman, 2011, Clinical Cancer Research.

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma

L. Trippa, N. Munshi, J. Laubach, 2019, American journal of hematology.

Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma★

R. Coleman, A. Friedman, R. Coleman, 2006, Journal of Neuro-Oncology.

Bevacizumab and daily temozolomide for recurrent glioblastoma

H. Friedman, D. Reardon, A. Desjardins, 2012, Cancer.

Tetanus toxoid and CCL3 improve DC vaccines in mice and glioblastoma patients

R. McLendon, A. Friedman, D. Bigner, 2015, Nature.

The Emerging Role of Anti-Angiogenic Therapy for Malignant Glioma†

D. Reardon, J. Rich, A. Desjardins, 2008, Current treatment options in oncology.

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.

Allan H Friedman, R. McLendon, A. Friedman, 2009, Neuro-oncology.

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

Allan H Friedman, R. McLendon, A. Friedman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.

R. McLendon, H. Friedman, D. Reardon, 2010, Neuro-oncology.

Phase II trial of gefitinib in recurrent glioblastoma.

Allan H Friedman, R. McLendon, A. Friedman, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support.

J. Perfect, J. Vredenburgh, M. Ross, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma

R. McLendon, A. Friedman, D. Bigner, 2006, Clinical Cancer Research.

Isodicentric chromosome 18q as sole abnormality in a histologically normal bone marrow from a patient with diffuse large-cell non-Hodgkin's lymphoma.

B. Davis, J. Vredenburgh, E. Ball, 1991, Cancer genetics and cytogenetics.

Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma

A. Friedman, D. Bigner, H. Friedman, 2008, Expert review of anticancer therapy.

Current available therapies and future directions in the treatment of malignant gliomas

D. Reardon, A. Desjardins, J. Vredenburgh, 2008, Biologics : targets & therapy.

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

A. Friedman, D. Bigner, J. Herndon, 2008, Clinical Cancer Research.

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.

Yiting Cao, Mark W Dewhirst, M. Dewhirst, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

T. Mikkelsen, W. Yung, M. Prados, 2011, Neuro-oncology.

Idiopathic Granulomatous Mastitis-A Mystery Yet to be Unraveled: A Case Series and Review of Literature

J. Vredenburgh, P. Bindal, S. Alexander, 2020, Cureus.

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma

E. Lipp, H. Friedman, A. Desjardins, 2018, The oncologist.

Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing

A. Friedman, L. Jones, H. Friedman, 2009, Journal of Neuro-Oncology.

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

R. McLendon, H. Friedman, D. Reardon, 2012, Journal of Neuro-Oncology.

CNS Metastasis and Ovarian Carcinoma. Is BRCA Mutation an Ally?-A Case Report

J. Vredenburgh, Meghana Singh, Radhika B Kulkarni, 2021 .

Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique.

R. Bast, J. Vredenburgh, W. Peters, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

The effects of hyperthermia in bone marrow purging of breast cancer.

T. Samulski, R. Dodge, S. Ingram, 1996, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies

D. Berry, A. Berchuck, E. Shpall, 1996, Cancer Chemotherapy and Pharmacology.

Intrabreath analysis of carbon monoxide uptake during exercise in patients at risk for lung injury.

N. MacIntyre, J. Vredenburgh, Y. Huang, 2006, Respiratory Medicine.

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.

G. Rosner, E. Winer, R. Bast, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.

G. Rosner, J. Kurtzberg, J. Vredenburgh, 1993, Blood.

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ)

H. Friedman, J. Kirkpatrick, A. Desjardins, 2016, Supportive Care in Cancer.

Targeting HER2 in the treatment of non-small cell lung cancer.

J. Vredenburgh, J. Wasser, N. Mar, 2015, Lung cancer.

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial

D. Tran, K. Fink, M. Mrugala, 2020, Clinical Cancer Research.

Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone.

L. Marks, E. Shpall, G. Broadwater, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.

S. Keir, D. Bigner, L. Muhlbaier, 2007, Neuro-oncology.

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low‐grade glioma

R. McLendon, E. Lipp, H. Friedman, 2012, Cancer.

Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma

H. Friedman, D. Reardon, A. Desjardins, 2011, Journal of Neuro-Oncology.

Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

R. McLendon, J. Provenzale, H. Friedman, 2007, Journal of Neuro-Oncology.

CT of the liver in patients with metastatic breast carcinoma treated by chemotherapy: findings simulating cirrhosis.

K. Washington, E. Paulson, M. Baker, 1994, AJR. American journal of roentgenology.

Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.

E. Shpall, H. Seigler, J. Vredenburgh, 1993, Journal of the National Cancer Institute.

A Rare Case of Clear Cell Adenocarcinoma of the Cervix with No Intrauterine Diethylstilbestrol Exposure

J. Vredenburgh, M. Hadfield, S. Alexander, 2020, Cureus.

A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma

R. McLendon, A. Friedman, D. Bigner, 2012, PloS one.

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

R. McLendon, A. Friedman, D. Bigner, 2011, Blood.

Molecularly targeted therapy for malignant glioma

D. Reardon, A. Desjardins, J. Vredenburgh, 2007, Cancer.

Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.

D. Berry, C. Cirrincione, D. Rizzieri, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of granulocyte‐macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous Done marrow after high‐dose chemotherapy

J. Kurtzberg, V. Hárs, J. Vredenburgh, 1995, European journal of haematology.

The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer.

J. Vredenburgh, M. Ross, W. Peters, 1994, Seminars in oncology.

Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia.

J. Vredenburgh, E. Ball, L. Mills, 1988, Medical and pediatric oncology.

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

R. McLendon, H. Friedman, D. Reardon, 2011, Cancer.

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

D. Bigner, H. Friedman, D. Reardon, 2009, Cancer.

Phase 1 trial of temozolomide plus irinotecan plus O6‐benzylguanine in adults with recurrent malignant glioma

R. McLendon, H. Friedman, D. Reardon, 2009, Cancer.

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

A. Friedman, H. Friedman, D. Reardon, 2012, International journal of radiation oncology, biology, physics.

Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial.

P. Wen, L. Freedman, A. Brenner, 2016 .

Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.

O. Craciunescu, H. Friedman, Z. Chang, 2013, International journal of radiation oncology, biology, physics.

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma

E. Lipp, H. Friedman, D. Reardon, 2013, Cancer medicine.

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.

Tom Mikkelsen, Randy Jensen, Patrick Y Wen, 2011, Neuro-oncology.

Primitive Neuroectodermal Tumor with Glioblastoma Multiforme Components in an Adult: A Collision Tumor

J. Vredenburgh, Victoria Forbes, 2016, Cureus.

New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature

J. Vredenburgh, A. Śliwińska, C. Bazewicz, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes.

L. Marks, G. Broadwater, D. Rizzieri, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The impact of conventional plus high dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local‐regional radiotherapy for breast cancer

G. Rosner, L. Marks, L. Prosnitz, 1994, Cancer.

Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration

R. McLendon, H. Friedman, D. Tucci, 2010, Journal of Neuro-Oncology.

Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with ≥ 10 positive axillary lymph nodes

G. Rosner, L. Marks, L. Prosnitz, 1992 .

Ado-trastuzumab emtansine: Avoiding side-effects of traditional HER2 positive breast cancer treatment

J. Vredenburgh, Alla Turshudzhyan, 2021, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support.

D. Berry, E. Shpall, G. Broadwater, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.

O. Colvin, G. Broadwater, W. Petros, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab

H. Friedman, A. Desjardins, J. Vredenburgh, 2016, Therapeutics and clinical risk management.

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

R. McLendon, H. Friedman, D. Reardon, 2009, Journal of Neuro-Oncology.

Predictors for pneumonitis during locoregional radiotherapy in high‐risk patients with breast carcinoma treated with high‐dose chemotherapy and stem‐cell rescue

L. Marks, T. Jamieson, L. Prosnitz, 2002, Cancer.

Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study

P. Wen, T. Cloughesy, L. Freedman, 2019, Neuro-oncology.

CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma—The Progress and the Limitations

A. Desjardins, J. Vredenburgh, N. Mar, 2015, Clinical Cancer Research.

The significance of microbial cultures of the hematopoietic support for patients receiving high-dose chemotherapy.

J. Perfect, J. Vredenburgh, C. Gilbert, 1996, Journal of hematotherapy.

Cytomegalovirus encephalomyelitis: MR imaging findings documenting response to ganciclovir therapy.

J. Provenzale, J. Vredenburgh, M. Arata, 1998, AJR. American journal of roentgenology.

2040 Predictors for pneumonitis during local-regional radiotherapy in patients with advanced breast cancer previously treated with high dose chemotherapy and bone marrow transplant

L. Marks, T. Jamieson, L. Prosnitz, 1997 .

Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence?

D. Rizzieri, N. Chao, J. Vredenburgh, 2004, Chest.

CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA

R. McLendon, D. Bigner, E. Thompson, 2021, Neuro-Oncology.

The impact of local/regional radiotherapy (RT), and its timing, on survival following lumpectomy/mastectomy and systemic chemotherapy in patients with ≥10 positive axillary nodes: Analysis of CALGB 9082

L. Norton, L. Marks, E. Shpall, 2004 .

Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support.

J. Vredenburgh, M. Ross, B. Meisenberg, 1994, Bone marrow transplantation.

A rare case of metastatic ectopic fibrolamellar hepatocellular carcinoma in a young healthy patient: A case report

J. Vredenburgh, J. Hundal, A. Nagaraj, 2021 .

Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.

Lawrence B Marks, Jinli Ma, Larry Norton, 2010, International journal of radiation oncology, biology, physics.

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.

G. Rosner, R. Schilsky, L. Norton, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Histologically benign, clinically aggressive: Progressive non‐optic pathway pilocytic astrocytomas in adults with NF1

R. McLendon, A. Olivi, R. Strowd, 2016, American journal of medical genetics. Part A.

Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.

A. Friedman, L. Jones, W. Hornsby, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants.

H. Lyerly, M. Morse, D. Rizzieri, 2002, Journal of hematotherapy & stem cell research.

Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study.

T. Cloughesy, H. Friedman, A. Das, 2010 .

Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)

H. Friedman, D. Reardon, J. Rich, 2008 .

Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results.

R. McLendon, H. Friedman, D. Reardon, 2010 .

Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas.

A. Friedman, H. Friedman, D. Reardon, 2009, Journal of Clinical Oncology.

Leptomeningeal Metastasis from Non-Small Cell Lung Cancer and Current Landscape of Treatments.

J. Vredenburgh, Meghana Singh, G. Ozcan, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG).

E. Lipp, H. Friedman, A. Desjardins, 2012 .

Lung adenocarcinoma with metastasis to the vitreous – A case report and review of literature

J. Vredenburgh, Meghana Singh, V. Thomas, 2021 .

Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM)

H. Friedman, D. Reardon, J. Rich, 2007 .

A family with Sertoli-Leydig cell tumour, multinodular goiter, and DICER1 mutation.

J. Vredenburgh, A. McAuliffe, P. Bindal, 2019, Current oncology.

8707 Clinical assessment of corticosteroid use and neurocognitive function in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study

T. Cloughesy, H. Friedman, A. Das, 2009 .

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients

A. Friedman, E. Lipp, H. Friedman, 2012, British Journal of Cancer.

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study

T. Mikkelsen, M. Prados, P. Wen, 2012, Journal of Neuro-Oncology.

A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.

E. Shpall, James R. Murphy, Y. Nieto, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B.

G. Rosner, L. Marks, L. Prosnitz, 1992, International Journal of Radiation Oncology, Biology, Physics.

Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study.

G. Rosner, L. Cartee, W. Petros, 1995, Cytokine.

Neurofibromatosis type 2

D. Reardon, J. Rich, A. Desjardins, 2007, Neurology.

Bevacizumab and daily temozolomide for recurrent glioblastoma

H. Friedman, D. Reardon, A. Desjardins, 2012, Cancer.

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

T. Mikkelsen, M. Prados, P. Wen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of Gliadel plus O6-benzylguanine (O6-BG) for patients with recurrent glioblastoma multiforme.

A. Friedman, H. Friedman, D. Reardon, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Emerging Role of Anti-Angiogenic Therapy for Malignant Glioma†

D. Reardon, J. Rich, A. Desjardins, 2008, Current treatment options in oncology.

Targeting HER2 in the treatment of non-small cell lung cancer.

J. Vredenburgh, J. Wasser, N. Mar, 2015, Lung cancer.

Current available therapies and future directions in the treatment of malignant gliomas

A. Desjardins, J. Vredenburgh, David A. Reardon, 2008 .

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

T. Mikkelsen, M. Prados, P. Wen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

R. McLendon, A. Friedman, K. Aldape, 2011, Neuro-oncology.

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.

R. Bast, L. Marks, J. Kurtzberg, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

R. McLendon, D. Bigner, H. Friedman, 2009, British Journal of Cancer.

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.

R. McLendon, A. Friedman, D. Bigner, 2011, Blood.

Everolimus tablets for patients with subependymal giant cell astrocytoma

H. Friedman, D. Reardon, A. Desjardins, 2011, Expert opinion on pharmacotherapy.

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

D. Bigner, H. Friedman, D. Reardon, 2009, Cancer.

Autologous bone marrow transplantation for acute myeloid leukemia following in vitro treatment with neuraminidase and monoclonal antibodies.

J. Vredenburgh, E. Ball, A. Howell, 1990, Bone marrow transplantation.

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low‐grade glioma

R. McLendon, E. Lipp, H. Friedman, 2012, Cancer.

Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting (CINV)

J. Vredenburgh, L. Barbato, H. Jhangiani, 2005 .